Is OKYO Pharma Ltd (OKYO) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 1.8% / 30% | 2.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 1.8% / 33% | 2.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 42.4% / 33% | 51.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 1.8% / 33% | 2.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 42.4% / 33% | 51.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -104.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Current Ratio | 0.6 |
| Total Assets | $4M |
Price & Trading
| Last Close | $1.58 |
| 50-Day MA | $1.85 |
| 200-Day MA | $2.24 |
| Avg Volume | 273K |
| Beta | -0.2 |
|
52-Week Range
$1.03
| |
About OKYO Pharma Ltd (OKYO)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is OKYO Pharma Ltd (OKYO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), OKYO Pharma Ltd is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is OKYO Pharma Ltd's debt ratio?
OKYO Pharma Ltd's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are OKYO Pharma Ltd's key financial metrics?
OKYO Pharma Ltd has a market capitalization of $80M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.